ARA-290 (Cibinetide) Nasal Spray
10 mg of the 11-residue erythropoietin helix-B surface peptide in bacteriostatic water, in a metered spray bottle. Made from a peptide lot tested in the manufacturer’s own laboratory, with a certificate.
| Compound | ARA-290 Cibinetide; erythropoietin helix-B surface peptide |
|---|---|
| CAS number | 1208243-50-8 |
| Molecular formula | C51H84N16O21 |
| Theoretical mass | 1257.3 Da |
| Sequence / structure | pGlu-EQLERALNSS-OH (11 residues; N-terminal pyroglutamate; free C-terminus) |
| Contents | ARA-290: 10 mg per bottle (≤ 0.1% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a metered nasal spray bottle |
| Storage, sealed | Store at 2–8 °C, protected from light; do not freeze |
| Format | Solution in a metered nasal spray bottle |
Sizes and lots
- 10 mg · 1 bottle — $78.99
- 10 mg · Kit of 10 — $702.22
ARA-290 (cibinetide) is a synthetic 11-residue peptide whose sequence reproduces the outward-facing surface of erythropoietin's helix B. Here it is supplied as 10 mg in sterile bacteriostatic water in a nasal spray bottle. Studies of the peptide have looked at tissue protection in rodent injury models and at small nerve fibre loss in short human trials; none of those cited here used the nasal route.
What is in the bottle
The safety data sheet lists 10 mg of cibinetide per bottle, at no more than 0.1% w/v, dissolved in bacteriostatic water containing 0.9% benzyl alcohol. In molar terms 10 mg is about 8.0 µmol. The peptide is not classified as hazardous. Benzyl alcohol carries hazard statements for harm when swallowed or inhaled, serious eye irritation and skin sensitisation.
Keep the bottle upright and capped at 2 to 8 °C, away from light, and do not let it freeze. General guidance on peptide solutions is in peptide storage and stability.
What the research covers
The tissue-protective effects of erythropoietin were traced to a receptor built from the EPO receptor and CD131. Brines and colleagues supported this with protein pull-down experiments in rat tissue and neuronal-like cells, and with CD131 knockout mice in which EPO no longer protected heart or spinal cord cells after injury1. Within EPO, the same group located the protective activity in helix B and showed that a short peptide mimicking its aqueous face protected tissue in rodent models without being erythropoietic2. Clinical work on the peptide has centred on sarcoidosis. A 22-person double-blind pilot in patients with small fibre neuropathy symptoms reported no safety concerns and a better neuropathy screening score than placebo after four weeks3.
The nasal route is a separate question that this literature does not address. None of the cited studies applied cibinetide to the nose, and none measured how much of an 11-residue, 1257.3 Da peptide crosses the nasal lining or where it goes afterwards. For this format the papers are background on the compound only. The full summary, including the corneal nerve trials, is on the ARA-290 10 mg vial page, and the guide to peptides for inflammation research compares cibinetide with other anti-inflammatory peptides.
Frequently asked questions
Is the spray the same peptide as the ARA-290 vial?
Yes. It contains cibinetide, pGlu-EQLERALNSS-OH, the same 11-residue sequence. The vial holds it as dry powder for the lab to dissolve; the spray holds 10 mg already in solution and is stored cold rather than frozen.
Has cibinetide been studied as a nasal spray?
Not in the papers cited on this page. The rodent studies and the human neuropathy trials did not use the nasal route, so no published finding on nasal delivery of cibinetide can be pointed to here.
References
- Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101(41):14907-12. DOI · PubMed
- Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008;105(31):10925-30. DOI · PubMed
- Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18(1):1430-6. DOI · PubMed
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.